Navigation Links
Semler Reports First Quarter 2017 Financial Results
Date:5/9/2017

PORTLAND, Ore., May 9, 2017 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the first quarter ended March 31, 2017.

"We believe that our products enable our customers to identify when preventive care options are appropriate, which allows them to intervene before events like heart attacks or strokes occur," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler. "Hence, the incentives for our customers to use our products include better clinical outcomes for their patients and better economics for their businesses," he added.

FINANCIAL RESULTSFor the three months ended March 31, 2017, compared to corresponding period of 2016, Semler had:

  • Revenue of $2,055,000, an increase of $554,000, compared to $1,501,000
  • Total operating expense, which includes cost of revenue, of $2,805,000, an increase of $372,000, compared to $2,433,000
  • Cost of revenue of $540,000, an increase of $123,000, compared to $417,000
  • Net loss of $871,000, or $0.17 per share, a decrease of $135,000, compared to a net loss of $1,006,000, or $0.20 per share
  • For the sequential three months ended March 31, 2017, compared to three months ended December 31, 2016, Semler had:

  • Revenue of $2,055,000, a decrease of $261,000, compared to $2,316,000
  • Total operating expense, which includes cost of revenue, of $2,805,000, an increase of $386,000, compared to $2,419,000
  • Cost of revenue of $540,000, an increase of $15,000, compared to $525,000
  • Net loss of $871,000, or $0.17 per share, an increase of $651,000, compared to a net loss of $220,000, or $0.04 per share
  • Cash of $159,000, a decrease of $463,000, compared to $622,000
  • FIRST QUARTER 2017 HIGHLIGHTSThe major accomplishments of the first quarter were as follows:

    1. Increased inventory and manufacturing capacity for our vascular testing product, QuantaFlo™, in preparation for anticipated continued customer base growth in 2017
                          
    2. Received new and expanded orders for QuantaFlo™, which we expect to be installed in the second quarter, resulting in continued sequential quarterly revenue growth as part of our recurring revenue model
                        
    3. Migrated more customers to QuantaFlo™ from its lower-priced predecessor product
                       
    4. Developed additional cybersecurity protections that are intended to aid our customers in complying with regulations regarding safeguarding personal health information

    In 2017, revenue from QuantaFlo™ is expected to grow due to an increasing number of installations, higher average pricing as compared to its predecessor product and the recurring revenue business models that we employ. We have received new and expanded orders in the first quarter that we have installed in the second quarter of 2017.

    Sequential results for first quarter 2017 compared to fourth quarter 2016 showed some decreases due to lower revenue from our fee-per-test customers, who primarily include home risk assessment service providers and who we believe historically conduct more business in the latter half of the calendar year than in the earlier months.  Also in the first quarter of 2017, operating expenses were impacted by higher expenditures, such as those for increased manufacturing and fulfillment capabilities, projects to improve cybersecurity measures and research and development projects.

    "Our immediate objective is to become the standard of care for testing to identify patients at risk for heart attacks and strokes to enable better preventive medical care," said Dr. Murphy-Chutorian.  "The first quarter performance was outstanding in this regard, particularly in growing our order book for fulfillment in the second quarter of 2017," he concluded.

    Notice of Conference CallSemler will host a conference call at 11 a.m. ET, Tuesday, May 9, 2017. The call will address first quarter results and will provide a business update on Semler's market outlook and strategies for the near-term future.

    The conference call may be accessed by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. Please specify to the operator that you would like to join the "Semler First Quarter 2017 Financial Results Call, conference ID# 7813537" The conference call will be archived on Semler's website at www.semlerscientific.com

    Semler Scientific, Inc. Statements of Operations(In thousands of U.S. Dollars, except for share and per share amounts)For the three months ended
    March 31 (Unaudited)20172016Revenue$

    2,0551,501Operating expenses:Cost of revenue540417Engineering and product development439270Sales and marketing988974General and administrative838772Total operating expenses2,8052,433Loss from operations(750)(932)Interest and other expense(116)(73)Other expense(5)(1)Interest and other expense(121)(74)Net loss $

    (871)

    $

    (1,006)Net loss per share, basic and diluted$

    (0.17)

    $

    (0.20)Weighted average number of shares used in computing basic and diluted loss per share5,231,2085,123,568

    Semler Scientific, Inc.Condensed Balance Sheets(In thousands of U.S. Dollars)As ofAs ofMarch 31, 2017December 31, 2016(Unaudited)Cash

    $

    159

    $

    622Other current assets 1,298970Noncurrent assets 1,6591,480Total assets 3,1163,072Current liabilities 5,8023,229Non-current liabilities5522,762Stockholders' deficit(3,238)(2,919)Total liabilities and stockholders' deficit

    $

    3,116

    $

    3,072

    About Semler Scientific, Inc.:Semler Scientific, Inc. is an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers.  Our mission is to develop, manufacture and market innovative proprietary products and services that assist our customers in evaluating and treating chronic diseases. Our first patented and U.S. Food and Drug Administration, or FDA, cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. In March 2015 we received FDA 510(k) clearance for the next generation version of this product named QuantaFlo™, which was commercially launched in August 2015 to more comprehensively evaluate our customers' patients for risk of heart attacks and strokes. We believe we are positioned to provide valuable information to our insurance company and physician customers, which in turn permit them to better guide patient care. Additional information about Semler can be found at semlerscientific.com.

    Forward-Looking StatementsThis press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "may," "will," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding growth in the customer base, continued revenue growth from QuantaFlo™ business, and the effects of the Company's cybersecurity measures. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such as whether or not insurance plans and other customers will continue to lease its cardiovascular testing products, along with those statements detailed in Semler Scientific's SEC filings, and involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

    CONTACT:Susan A. Noonan
    S.A. Noonan Communications
    susan@sanoonan.com
    212 966 3650

     

    To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/semler-reports-first-quarter-2017-financial-results-300453962.html


    '/>"/>
    SOURCE Semler Scientific, Inc.
    Copyright©2017 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Semler Reports Second Quarter 2015 Financial Results
    2. Semler to Report Second Quarter 2015 Financial Results and Host Conference Call on July 31, 2015
    3. Semler Reports First Quarter 2015 Financial Results
    4. Semler Adds Top Insurance Plan to Customer List
    5. Semler Reports 2014 Annual and Fourth Quarter Financial Results
    6. Semler Reports Third Quarter 2014 Financial Results
    7. Semler Reports Second Quarter 2014 Financial Results
    8. Effective Microorganisms (EM) Market Sales, Revenue and Industry Growth Rate 2017-2022, Available at ReportsnReports.com
    9. Gene-Eden-VIR/Novirin vs. Antiviral Drugs, CBCD Reports High Interest in the Comparison Between Natural Treatments and Approved Drugs
    10. Orphan Drugs Market Growing at a CAGR of 10.20% During 2017 to 2021, Says a New Report at ReportsnReports.com
    11. H1 Pipeline on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) for 2017 Market Therapeutics Growth and Assessment at ReportsnReports.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
    (Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
    (Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
    Breaking Medicine Technology:
    (Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... preserve fertility and create life. Although frozen embryos have a slight statistical advantage ... , “Egg freezing is a wonderful opportunity for women undergoing medical treatment or ...
    (Date:9/21/2017)... Aliso Viejo, CA (PRWEB) , ... September 21, 2017 , ... ... never been so fun and easy to do. Users can select from up to ... more all with a click of a mouse all within Final Cut Pro ...
    (Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... Sept. 26, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      ... easy to get things wrong, run afoul of The Quality System Regulation (§820.250), ...
    (Date:9/21/2017)... ... September 21, 2017 , ... ... Infinity Behavioral Health Services for professionals in the addiction treatment industry entitled: ... . , Insurance companies and state and federal governments are increasingly scrutinizing ...
    (Date:9/21/2017)... IL. (PRWEB) , ... September 21, 2017 , ... ... results released today of a new member survey conducted by the International ... restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures ...
    Breaking Medicine News(10 mins):